You are here:Home-Inhibitors & Agonists-Ras-Raf-MAPK-ERK Pathway-Raf

Request The Product List ofRaf Raf

Cat. No. Product Name CAS No. Information



SB-699393 is a potent, selective and CNS penetrant B-Raf inhibitor with Kd of 7.2 nM; possesses enhanced CNS penetration (BB ratio=0.8:1) compared with SB-590885.




Belvarafenib (HM95573, GDC5573) is a novel potent, selective RAF inhibitor with IC50 of 41 nM, 7 nM and 2 nM for BRAF WT, BRAF V600E and CRAF, respectively; inhibits cell proliferation of A375 (BRAF V600E) and SK-MEL-30 (NRAS Q61K) with IC50 of 57 and 24 nM, also inhibits the phosphorylations of MEK and ERK downstream kinases in mutant BRAF and mutant NRAS melanoma cells; shows the excellent antitumor activity in mouse models xenografted with both of BRAF mutation cell lines (e.g. A375 and SK-MEL-28) and NRAS mutation cell lines.




BGB-283 (Lifirafenib, BGB283) is a potent pan RAF inhibitor of BRAF V600E, wt BRAF, CRAFY340/341D and wt ARAF (IC50=5-40 nM); inhibits recombinant BRAFV600E with IC50 of 23 nM; also inhibits EGFR and EGFR T790M/L858R with IC50 of 29 nM and 495 nM respectively; potently inhibits BRAF(V600E)-activated ERK phosphorylation and cell proliferation in vitro; shows tumor growth inhibition in both cell line-derived and primary human colorectal tumor xenografts bearing BRAF(V600E) mutation.

Colon Cancer



AZ 628


AZ 628(AZ-628, AZ628) is a potent and selective B-Raf inhibitor with IC50s of 2.14 uM and 0.19 uM for wt Braf and Braf V600E respectively.



1800398-38-2 LXH254 (LXH-254, LXH 254) is a novel potent, ATP-competitive pan-RAF inhibitor, binds to Raf proteins and inhibits Raf-mediated signal transduction pathways, inhibits proliferation of Raf-overexpressing tumor cells; demonstrates anti-proliferative activity in cell lines that contain a variety of mutations that activate MAPK signaling, blocks mutant RAS-driven signaling and cell proliferation; demonstrates tumor regression in several KRAS-mutant models including the NSCLC-derived Calu-6 (KRAS Q61K) and NCI-H358 (KRAS G12C), exhibits efficacy in numerous MAPK-driven human cancer cell lines and in xenograft tumors representing model tumors harboring human lesions in KRAS, NRAS and BRAF oncogenes.

Lung Cancer

Phase 1 Clinical



863029-99-6 Balamapimod (MKI-833) is an orally active, reversible Ras/Raf/MEK inhibitor developed for antineoplastic potential.


131916-62-6 RRD-251 hydrochloride is a small molecule disruptor of Rb/Raf-1 interaction, potently and selectively disrupts the Rb/Raf-1 (IC50=77 nM) but not Rb/E2F, Rb/prohibitin, Rb/cyclin E, and Rb/HDAC binding; inhibits Rb to recruit Raf-1 to proliferative promoters and inhibited E2F1-dependent transcriptional activity; inhibits anchorage-dependent and anchorage-independent growth of human cancer cells; significantly inhibits tumor growth in tumors with functional Rb in vivo.

Request The Product List

* Indicates a Required FieldYour information is safe with us.

  • *Product List:
  • *Applicant name:
  • *Email address:
  • *Organization name:
  • *Country:
  • Additional Information:
Contact Us